Usually, the screening starts for 50-year-old men, but for high-risk individuals (germline mutations in BRCA1, BRCA2, ATM, CHEK2; family history of PC) the screening should commence as early as age 40 [36]. Here, BRCA2 is linked to pachyonychia congenita.